.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,683,087

« Back to Dashboard

Details for Patent: 7,683,087

Title:N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl] -p-amino benzoic acids as HIV reverse transcriptase inhibitors
Abstract: A series of S-triazolyl .alpha.-mercaptoacetanilides having N-(.alpha.-mercaptoacetyl) p amino benzoic acid derivatives. ##STR00001## are provided, where Q is CO.sub.2H, or a salt or ester thereof, or a C(O) N-linked amino acid. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.
Inventor(s): Girardet; Jean-Luc (Aliso Viejo, CA), de la Rosa; Martha (Fountain Valley, CA), Hong; Zhi (Chapel Hill, NC), Lang; Stanley (Laguna Niguel, CA)
Assignee: Ardea Biosciences, Inc. (San Diego, CA)
Filing Date:Aug 18, 2008
Application Number:12/193,599
Claims:1. A compound of formula ##STR00105## wherein: Ar is ##STR00106## R.sup.1 is selected from the group consisting of Cl, Br, I, CH.sub.3, CF.sub.3, CHF.sub.2, and CH.sub.2F; X is O or NH; R.sup.2 is H, a pharmaceutically acceptable cation or C.sub.1-3 alkyl, when X is O; or XR.sup.2 is NHCH.sub.2CH.sub.2COOR.sup.13 or NHCH(R.sup.12)COOR.sup.13 where R.sup.12 is C.sub.1-4 alkyl or aryl-C.sub.1-4 alkyl and R.sup.13 a pharmaceutically acceptable cation or C.sub.1-3 alkyl; R.sub.3 is H or CH.sub.3; R.sup.0 is selected from the group consisting of Cl, Br, CF.sub.3 and methyl; R.sup.P is selected from the group consisting of methyl, ethyl, propyl, isopropyl, cyclopropylmethyl, and C.sub.3-6 cycloalkyl; R.sup.6 is H, F, Cl, Br, CH.sub.3, CF.sub.3, CFH.sub.2, CF.sub.2H, ethyl, isopropyl, cyclopropyl, OCH.sub.3, OH, OCF.sub.3, NH.sub.2 or NHCH.sub.3; and R.sup.7 is selected from the group consisting of Cl, Br, I, CH.sub.3, CF.sub.3; OCH.sub.3, isopropyl, cyclopropyl, tert-butyl, cyclobutyl, and methyl.

2. The compound of claim 1, wherein X is O.

3. The compound of claim 2, wherein R.sup.6 is not OH, NH.sub.2 or NHCH.sub.3.

4. The compound of claim 2, wherein Ar is not substituted phenyl and at least one of R.sup.4, R.sup.5, and R.sup.6 is other than H or CH.sub.3.

5. The compound of claim 1, which is 4-[2-(5-bromo-4-[2-chloro-4-cyclopropyl-6-methylphenyl]-4H-1,2,4-triazol-- 3-ylthio)acetamido]-3-chlorobenzoic acid or an ester or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1, wherein R.sup.2 is H.

7. The compound of claim 3, wherein Ar is a substituted quinoline or isoquinoline and R.sup.1 is selected from the group consisting of Br, CF.sub.3, CFH.sub.2, and CF.sub.2H.

8. The compound of claim 7, wherein each of R.sup.4, R.sup.5, and R.sup.6 is H.

9. The compound of claim 7, wherein R.sup.P is cyclopropyl.

10. The compound of claim 7, wherein R.sup.1 is Br and R.sup.0 is Cl.

11. The compound of claim 1, wherein R.sup.2 is H or a pharmaceutically acceptable cation.

12. The compound of claim 1, wherein R.sup.1 is Cl or Br.

13. The compound of claim 12, wherein R.sup.1 is Br.

14. The compound of claim 1, wherein R.sup.1 is Br, CF.sub.3, CFH.sub.2 or CF.sub.2H.

15. The compound of claim 14, wherein R.sup.1 is CF.sub.2H.

16. The compound of claim 1, wherein R.sup.3 is H.

17. The compound of claim 1, wherein R.sup.0 is Cl.

18. The compound of claim 1, wherein R.sup.0 is Cl and X is O.

19. The compound of claim 1, wherein R.sup.6 is not H or CH.sub.3.

20. The compound of claim 1, wherein R.sup.P is alkyl.

21. The compound of claim 20, wherein R.sup.P is methyl.

22. The compound of claim 1, wherein R.sup.P is C.sub.3-6 cycloalkyl.

23. The compound of claim 22, wherein R.sup.P is cyclopropyl.

24. The compound of claim 1, wherein R.sup.6 is not H.

25. The compound of claim 1, wherein R.sup.6 is H, Cl, CH.sub.3, CF.sub.3 or ethyl.

26. The compound of claim 1, wherein R.sup.7 is Cl, CH.sub.3 or CF.sub.3.

27. The compound of claim 1, wherein R.sup.1 is Br or CF.sub.2H; R.sup.3 is H; R.sup.0 is Cl; and R.sup.2 is H or a pharmaceutically acceptable cation.

28. The compound of claim 27, wherein R.sup.P is C.sub.3-6 cycloalkyl.

29. The compound of claim 28, wherein R.sup.P is cyclopropyl.

30. The compound of claim 1, wherein at least one of R.sup.6 or R.sup.7 is not H.

31. The compound of claim 30, wherein R.sup.6 is H and R.sup.7 is Cl, Br, CH.sub.3 or CF.sub.3.

32. The compound of claim 1, wherein R.sup.6 and R.sup.7 are each independently selected from Cl, Br, CH.sub.3 and CF.sub.3.

33. The compound of claim 1, wherein R.sup.6 is not H.

34. The compound of claim 33, wherein R.sup.6 in the ortho position, relative to the triazole ring.

35. The compound of claim 1, wherein R.sup.6 and R.sup.7 are both not H.

36. The compound of claim 35, wherein R.sup.6 and R.sup.7 are both in the ortho position, relative to the triazole ring.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc